Lazard Challenges Centerview for Role in Venezuela’s Massive Debt Restructuring 
Australia’s Atlas Arteria Rejects IFM Global’s Increased A$7.4 Billion Takeover Offer 
Gold Prices Surge Above $4,300 as US-Iran Peace Deal Weakens Dollar and Oil 
Taiwan Central Bank Likely to Keep Interest Rates Unchanged Through 2027 
BOJ Raises Interest Rates to 31-Year High, Signals Strong Focus on Inflation Risks 
Woodside Energy Denies Exxon Mobil Takeover Talks Amid LNG Growth Focus 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
Elon Musk Becomes World's First Trillionaire After SpaceX IPO Surge 
OpenAI's $34B Spending Pushes AI Market Leadership Ahead of IPO 
RBA Expected to Hold Interest Rates at 4.35% as Markets Watch AUD/USD and ASX 200 
US-Iran Ceasefire Deal Extends Peace Talks and Eases Oil Trade Restrictions 
Trump Administration Closes Delta Air Lines Investigation Over 2024 CrowdStrike Outage 
Microsoft Taps AWS to Support GitHub Amid AI Coding Boom 
Wall Street Surges as US-Iran Deal Eases Oil Price and Inflation Concerns 
DOJ Clears Paramount Skydance-Warner Bros. Discovery Merger Without Conditions 
GM Explores Defense Manufacturing Partnership With Lockheed Martin 
Celltrion Healthcare will bring its parent company’s adalimumab biosimilar called Yuflyma to Europe next month. The company is in charge of Celltrion’s businesses overseas, and it will be launching the said biosimilar drug and start its sale in European countries.
The launch of Yuflyma
As per The Korea Herald, Celltrion will introduce Yuflyma in six European regions at first. A company official reportedly said that they will attempt to release the product in Spain this coming June, but this date could still change.
Celltrion’s Yuflyma is said to be the world’s first biosimilar of Humira, the original drug containing adalimumab and made by AbbVie pharmaceutical company, a spin-off of Abbott Laboratories.
In the third quarter of this year, Celltrion Healthcare is aiming to launch the drug in seven additional European countries and will include France and Germany. In the last quarter, it will roll out in three more regions, including Italy.
Approval of Celltrion’s Biosimilar
The European Commission handed down the authorization for Yuflyma in February. The agency approved it for use in Europe for the treatment of patients suffering from 13 chronic inflammatory diseases such as rheumatoid arthritis, Crohn’s disease, pediatric uveitis, juvenile idiopathic arthritis, and ulcerative colitis.
Celltrion Healthcare shared that the company was given the EU marketing authorization for the high-concentration, citrate-free adalimumab biosimilar. It will be sold under the Yuflyma brand name, which was called the CT-P17 when it was still being developed.
The citrate-free and high concentration formulation, which is 100mg/mL, was applied to lessen the dosage of the existing drug by half. In comparison, most of the Humira biosimilars have low concentrations of the drug.
The Center for Biosimilars stated that the approval is notable because even if the European market has many adalimumab biosimilars already, this one coming from Celltrion has no citrate, a substance that is said to make the drug administration painful for patients. Apparently, it was removed to avoid pain.
Celltrion’s entrance into the adalimumab manufacturing also makes it the first to compete in this new market but with a lower-cost biosimilar. Meanwhile, the approval from the EU commission was followed by positive opinions from the European Medicines Agency (EMA) and the Committee for Medicinal Products for Human Use (CHMP).
